Jazz Pharmaceuticals, Inc. (JAZZ) Reports In-Line Q3 EPS; Guides Above the Street
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $240.74 -1.27%
Revenue Growth %: +7.1%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +7.1%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q3 EPS of $0.94, in-line with the analyst estimate of $0.94. Revenue for the quarter came in at $73.3 million versus the consensus estimate of $72.03 million.
Jazz Pharmaceuticals, Inc. sees FY2011 EPS of $3.45-$3.50, versus the consensus of $3.44.
Jazz Pharmaceuticals, Inc. sees FY2011 EPS of $3.45-$3.50, versus the consensus of $3.44.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS says this pharma name offers a robust case for stock outperformance
- Yeti outlines growth targets and financial framework through 2030
- Amer Sports raises Q3 2026 outlook, updates long-term targets
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
